Shares of St. Jude Medical Inc. (NYSE:STJ) hit a new 52-week high on Monday . The stock traded as high as $80.91 and last traded at $80.67, with a volume of 652,496 shares. The stock had previously closed at $80.58.

STJ has been the subject of several research reports. Nomura Holdings Inc. initiated coverage on shares of St. Jude Medical in a research report on Wednesday, March 16th. They issued a “buy” rating and a $64.00 price target for the company. BMO Capital Markets upped their price target on shares of St. Jude Medical from $66.00 to $73.00 and gave the company an “outperform” rating in a research report on Monday, March 28th. Canaccord Genuity upped their price target on shares of St. Jude Medical from $42.00 to $51.00 and gave the company a “sell” rating in a research report on Monday, March 28th. Cowen and Company upgraded shares of St. Jude Medical from a “market perform” rating to an “outperform” rating and upped their price target for the company from $66.00 to $73.00 in a research report on Monday, March 28th. Finally, Jefferies Group upped their price target on shares of St. Jude Medical from $55.00 to $65.00 and gave the company a “hold” rating in a research report on Monday, March 28th. Twenty research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. St. Jude Medical presently has an average rating of “Hold” and a consensus price target of $73.85.

The stock’s 50-day moving average price is $77.93 and its 200-day moving average price is $63.92. The stock has a market cap of $22.99 billion and a P/E ratio of 32.49.

St. Jude Medical (NYSE:STJ) last issued its quarterly earnings data on Wednesday, April 20th. The medical technology company reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.02. The company had revenue of $1.45 billion for the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the prior year, the firm earned $0.93 earnings per share. St. Jude Medical’s revenue for the quarter was up 7.7% compared to the same quarter last year. Equities research analysts predict that St. Jude Medical Inc. will post $4.06 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 29th. Investors of record on Thursday, June 30th will be paid a dividend of $0.31 per share. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.53%. The ex-dividend date is Tuesday, June 28th.

Other large investors recently modified their holdings of the company. Deimos Asset Management LLC bought a new stake in shares of St. Jude Medical during the fourth quarter worth $1,050,000. Commerzbank Aktiengesellschaft FI boosted its stake in shares of St. Jude Medical by 113.1% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 17,104 shares of the medical technology company’s stock worth $1,057,000 after buying an additional 9,077 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of St. Jude Medical by 2.0% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,468 shares of the medical technology company’s stock worth $1,141,000 after buying an additional 366 shares in the last quarter. Numeric Investors LLC boosted its stake in shares of St. Jude Medical by 397.4% in the fourth quarter. Numeric Investors LLC now owns 18,900 shares of the medical technology company’s stock worth $1,167,000 after buying an additional 15,100 shares in the last quarter. Finally, Advisors Asset Management Inc. boosted its stake in shares of St. Jude Medical by 32.6% in the fourth quarter. Advisors Asset Management Inc. now owns 20,002 shares of the medical technology company’s stock worth $1,236,000 after buying an additional 4,916 shares in the last quarter.

St. Jude Medical, Inc is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.